Middletown, DE -- (SBWIRE) -- 09/11/2013 -- VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way. Today our focus is on: Infinera Corp. (NASDAQ:INFN), Fifth Street Finance Corp.(NASDAQ:FSC), Opexa Therapeutics Inc(NASDAQ:OPXA), Intersil Corp(NASDAQ:ISIL)
Infinera Corp.(NASDAQ:INFN) was a volume gainer of 1.71 million shares and the average volume of the stock remained 1.35 million shares. The stock opened the session at $11.05 and finished at the end of the day at $11.09 and the stock escalated +0.82%.The market capitalization of the stock remained 1.31 billion. The half-yearly trend of the stock remained positive +54.24%. Infinera Corporation provides optical networking equipment, software, and services to communications service providers, Internet content providers, cable operators, and subsea network operators worldwide.
For How Long INFN will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, Fifth Street Finance Corp. (NASDAQ:FSC) exchanged 1.53 million shares and the average volume remained 826,261.00 shares. The stock closed the session at $10.70 with the gain of +1.23%. Tracking three months and 6 months trends, the stock was at of +1.90% and -2.46%, respectively. Fifth Street Finance Corp. is a business development company specializing in investments in middle market, bridge financing, first and second lien debt financing, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, and management buyouts in small and mid-sized companies.
Will FSC Continue To Move Higher? Find Out Here
Opexa Therapeutics Inc (NASDAQ:OPXA) decreased -3.03% and its closing price was $1.60. The volume of the stock was 1.66 million shares and the average volume remained 2.58 million shares. Yesterday, the stock traded amid the day price range of $1.55 - $1.74. The market capitalization of the stock remained 32.18 million. The beta of the stock remained 1.65. Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its leading therapy candidate includes Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS.
Will OPXA Get Buyers Even After The Recent Rally? Find Out Here
Intersil Corp (NASDAQ:ISIL) exchanged 1.64 million shares in the previous trading session, and its average trading remained 1.59 million shares. ISIL advanced +0.83% and it closed the trading at $10.89. The market capitalization of the stock remained 1.39 billion. YTD trend of the stock was positive +34.44%. Intersil Corporation designs, develops, manufactures, and markets analog, mixed-signal, and power management integrated circuits (ICs) for applications in the industrial and infrastructure, personal computing, and consumer electronics markets.
For How Long ISIL’s Gloss will Attract Investors? Find out via this report
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!
Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.
VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.
Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)